Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source reviews Japan's extensive 2014 reforms and investments in regenerative medicine, exploring the government's initiatives to accelerate stem cell research while maintaining safety and efficacy.

This case study describes a 21-year-old man who experienced a hemorrhagic stroke potentially linked to finasteride and minoxidil use for androgenic alopecia, emphasizing the need for thorough medication history in young stroke patients.

This report describes two cases of stroke associated with finasteride use for male-pattern hair loss, suggesting a potential link to thrombosis due to increased estrone and estradiol levels.

This review discusses recent advances in polydopamine-based biomaterials and their growing potential in personalized medicine, but reports no new experimental results; the authors highlight both opportunities and challenges for future applications.

This study presents a case where a young male with cryptogenic stroke and patent foramen ovale, using finasteride, experienced symptomatic improvement after PFO closure and discontinuing finasteride, suggesting cardiovascular risks associated with the drug.

This report details a case study where a 40-year-old woman experienced allergic contact dermatitis and angioedema-like symptoms after using PPD-containing hair dye. Patch testing confirmed a positive reaction to PPD, highlighting the substance's potential to cause both T-cell and IgE-mediated hypersensitivity reactions.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study found that human placenta hydrolysate reduced SARS-CoV-2 replication and improved immune response in ferret models, suggesting potential as a COVID-19 treatment.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

This study reviewed the dosages of products approved in Japan from 2003-2010 and found that 28.1% were at different levels than in the U.S., with limited evidence suggesting different clinical responses.

This review discusses the distinction between platelet-rich plasma and stem cell-based therapies in regenerative medicine, highlighting their different roles and stressing the importance of honest representation by commercial and health entities.

This review discusses the impaired functionality of regulatory T cells in the pancreas during the development of Type 1 diabetes, highlighting their role in disease pathogenesis, potential of Treg-based therapies, and challenges in clinical applications.

This study found that nearly all nurses caring for chemotherapy patients showed detectable levels of cyclophosphamide in their urine, indicating significant occupational exposure to this antineoplastic drug.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This review in SEDA Volume 40 summarizes new adverse reaction data for diuretics published in 2017, highlighting specific risks such as fractures with loop diuretics and hyperkalemia with spironolactone.

This review examines the impact of biotin, vitamin B12, and zinc on male reproduction, emphasizing their role in spermatogenic failure, but reports no new clinical results.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This review examines the regulatory frameworks and definitions of quasi-drugs in South Korea and Japan, where cosmeceuticals like medicated shampoos and anti-hair loss agents are developed and marketed, providing consumers with more hygienic and preventive care options under specific safety and effectiveness oversight.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study suggests a decision tree using in vitro metabolic clearance to identify early drug candidates likely to experience nonlinear pharmacokinetics due to intestinal CYP3A-related metabolism.

This chapter provides an overview of phytochemicals with properties to combat alopecia and discusses the potential of flavonoids, found in several herbs, as a safer alternative to synthetic hair loss treatments due to their long-term skin compatibility.

This study found that para-phenylenediamine induces cytotoxic effects in normal human hair dermal papilla cells by altering microRNA expression and causing cell death, cell cycle arrest, and oxidative stress.

PMS nanoparticles improve damaged hair by protecting and restoring its surface and color.

This article highlights the health risks associated with adding paraphenylenediamine to mehndi, such as contact dermatitis and asthma, and emphasizes the need for regulatory checks as its use grows among cancer patients, women with alopecia, and pregnant individuals.

The researchers reported that corticosteroid treatments for alopecia areata led to clinical improvement but did not significantly alter oxidative stress markers, suggesting a limited regulatory effect on these systems.

The researchers reported that both finasteride and PM-9 competitively inhibit the 5 alpha-reductase enzyme in P. crustosum broth.

This study developed and validated a precise RP-HPLC-PDA method for estimating finasteride in bulk and tablet forms, suitable for quality control use.

This study indicates that individuals exposed to PPD mount varying immune responses, with either tolerance, subclinical inflammation, or allergy, suggesting no true non-responders to PPD.